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Pituitary incidentalomas are a by-product of modern imaging technology. the term ‘incidentaloma’ is neither 
a distinct diagnosis nor a pathological entity. Rather, it is a collective designation for different entities that are 
discovered fortuitously, requiring a working diagnosis based on the input of the radiologist, endocrinologist 
and often a neurosurgeon. In addition to pathological conditions affecting the pituitary gland, a thorough 
knowledge of the radiological characteristics of normal variants and technical artifacts is required to arrive at an 
accurate differential diagnosis. after careful radiological and hormonal evaluation, the vast majority of pituitary 
incidentalomas turn out to be non-functioning pituitary microadenomas and Rathke’s cleft cysts (Rccs). Based on the 
low growth potential of non-functioning pituitary microadenomas and Rccs, periodic MRI surveillance is currently 
considered the optimal management strategy. stricter follow-up is required for macroadenomas, as increases in size 
occur more frequently.
Introduction
New diagnostic and therapeutic methods influence 
medicine in many positive ways. However, besides 
the obvious benefits they also have some unintended 
consequences. Modern radiological investigations are 
no exception. High-resolution imaging provides the 
opportunity to visualize anatomical structures more 
clearly. On the other hand, it increases the number of 
findings that are unrelated to the reason for the original 
scan. Hence, it is a challenge to know what to do when 
faced with such ‘diseases of modern technology’ that are 
often termed incidentalomas.
The term ‘incidentaloma’ can be applied to a random 
discovery in any organ. In everyday clinical practice, 
incidentalomas are most frequently found in kidneys, 
thyroid gland, liver, adrenal glands and pituitary gland. 
However, incidentalomas of endocrine glands present 
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additional challenges not only for their high prevalence, 
but also for the risk of autonomous hormonal activity or 
for impairing normal glandular function. As frank clinical 
manifestations are characteristically absent, resolving 
the true hormonal status of incidentalomas may be 
challenging. Recent progress in neuroimaging has resulted 
in increased recognition of sellar and parasellar lesions. 
In order to be termed as a pituitary incidentaloma, the 
imaging investigation should be performed in patients 
without overt signs and symptoms of pituitary disease. 
Pituitary adenomas and Rathke’s cleft cysts (RCCs) are 
the most frequently encountered incidentally discovered 
entities in the pituitary region. However, the differential 
diagnosis of an incidentally discovered sellar mass is much 
broader and includes a large number of other entities 
(Table 1) (1).
The aim of this review is to discuss the differential 
diagnosis of pituitary incidentalomas from the radiologist’s 
and endocrinologist’s perspectives.
How frequent are pituitary incidentalomas?
Data on the prevalence of pituitary incidentalomas 
is generally derived from retrospective autopsy and 
imaging studies. The estimated figures vary widely from 
1.5 to 38% depending on the era of the study and the 
study population. This variability reflects differences in 
definitions of pituitary incidentaloma used by the authors 
(asymptomatic, non-functioning pituitary adenoma or 
incidentally noted lesion); the type of the study (autopsy 
or radiological) and the imaging technique (CT, 1.5 T or 
3.0 T MRI) (2, 3).
In the largest meta-analysis of autopsy studies 
comprising 18  902 examined pituitaries from 32 series, 
the mean prevalence of pituitary incidentaloma was 
10.7% (range 1.5–31%) (2). Lesions were uniformly 
distributed between sexes and among adult age groups. 
Importantly, the prevalence of macroadenomas in autopsy 
series is <1% (2). Some studies report slightly increased 
prevalence in the elderly population (4, 5). Kastelan and 
Korsic suggested that an age-related decline in peripheral 
hormonal secretion could lead to compensatory feedback 
stimulation of gonadotropic cells, thereby stimulating the 
early stages of pituitary tumor development (4).
The radiological prevalence of incidentalomas in 
the sellar and parasellar regions has increased with 
technological advances (6, 7, 8, 9, 10). Earlier studies were 
performed using CT, which is considered less sensitive 
than MRI for detecting lesions of the pituitary. Pituitary 
incidentalomas detected during PET have also been 
reported in clinical case studies and in retrospective series 
of patients with cancer (11, 12, 13, 14, 15). MRI studies 
in unselected populations report micro-incidentaloma 
rates of 10–38% (16, 17). Similar to autopsy series the 
percentage of macroadenomas is quite low: 0.2% in CT 
series (18) and 0.16–0.3% in MRI studies (19, 20). These 
data derived from normal populations or apparently 
asymptomatic patients are in contrast with the prevalence 
of clinically relevant pituitary adenomas, which is closer 
to 1 case per 1064–1200 (21, 22). It is clear that few of 
the incidentally discovered microadenomas in pathology 
and radiology series progress to macroadenomas (2, 3). 
The proportion of macroadenomas, however, is higher 
in some neuroradiological series, where imaging was 
performed in patients with non-specific symptoms/signs 
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(23, 24, 25, 26). In the largest series of incidentally 
discovered pituitary lesions, imaging was performed 
most often for investigation of headache (40%). Other 
indications included trauma, cerebrovascular accidents 
or transient ischemic attacks, sinusitis, cervical spine 
disorders, visual loss, and syncope (23, 25, 27, 28).
Currently MRI is the modality of choice for detailed 
assessment of the majority of pituitary lesions, while 
CT has a supplementary role mainly for its advantages 
in the evaluation of changes in bone structure of the 
sella and calcifications (29). The increasing use of high-
field MRI allows for multiplanar high contrast images of 
the pituitary and its adjacent structures. Noise artifacts 
inherent to high-resolution scanning may pose additional 
challenges when interpreting acquired images.
Pitfalls in pituitary imaging
While individual practices vary from center to center, 
pituitary MRI studies usually include pre-contrast 
T1-weighted and T2-weighted spin-echo coronal and 
sagittal sections with thin slices. Coronal and/or sagittal 
T1-weighted spin-echo gadolinium-enhanced images 
are also often acquired. In order to gain the maximum 
amount of clinically useful information, the following 
items should be obtained: use of high matrix size (512), 
coronal spin-echo T1-weighted and fast spin-echo 
T2-weighted images, sagittal and axial T1-weighted images 
(to fully evaluate the posterior pituitary), and careful use 
of gadolinium contrast agents (30). Properly performed 
volumetric assessments can be helpful for follow-up of 
lesion progression, but these are often not performed in 
the routine setting when a sellar lesion is discovered by 
chance. While not used routinely, axial sequences can be 
of significant additional use in the differential diagnosis 
of certain sellar lesions. Diagnostic pitfalls can be avoided 
by using pulse sequences adapted for the sella and by 
recognizing artifacts such as magnetic susceptibility, 
partial volume, chemical shift or pulsatility. Occasionally 
some incidental findings may be variants of the normal 
pituitary.
The small sella
The inter-individual variability of the size of the sella 
turcica sometimes produces a pseudoenlargement of the 
pituitary on images where a normal-sized pituitary is 
visualized in a relatively small sella (31, 32). This normal 
anatomical variant can be mistaken for an enlargement 
of the content of the pituitary fossa and can lead to an 
incorrect diagnosis of a pituitary mass such as isointense 
pituitary adenoma or ‘pituitary hyperplasia’. In adults, 
hyperpneumatization of the sphenoid sinus may be 
associated with a small sella since the pneumatization 
of the sinus may limit the depth of the pituitary fossa. 
In such cases the pituitary gland may project beyond the 
sellar aperture. A thick dorsum sellae, either pneumatized 
or consisting of fat and bone, can decrease the 
anteroposterior pituitary fossa diameter. Furthermore, in 
adolescent females the presence of a small or narrow sella 
Figure 1
small sella. sagittal t1-weighted images show (a) small or flat sella, extensive pneumatization of sphenoid sinus, and a bulging 
normal pituitary gland; and (B) small sella and thick dorsum sellae (arrow). coronal t1-weighted image after contrast 
enhancement shows marked upward bulging of the normal pituitary gland with extensive sphenoid sinus pneumatization and a 
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can increase the physiological convexity of the pituitary 
(Fig. 1). Therefore, in cases of an enlarged pituitary gland 
with normal T1 and T2 signals and normal enhancement 
after gadolinium injection, a small sella should be 
considered in the differential diagnosis. The degree of 
the pneumatization of the sphenoid sinus, the shape 
of the dorsum sellae and the width of the sella should 
also be taken in account. Other possible conditions 
that may be associated with upward convexity of the 
pituitary gland include isointense holosellar pituitary 
adenoma and an isointense Rathke’s cleft cyst which 
are infrequent (Fig. 2). Although rare, the volume of a 
normal-sized sella can also be reduced by an unusually 
large inferior coronary sinus, a sellar spine or a medial 
deviation of the internal carotid arteries (‘kissing’ carotid 
arteries) or trigeminal arteries (Fig. 3).
Physiological and secondary pituitary enlargement
Another incidental finding on neuroimaging is an 
increase in pituitary size following physiological 
hypertrophy of pituitary cells (33). A number of imaging 
studies of healthy volunteers reported sex-dependent 
and age-dependent variations in size and contour of 
normal  pituitary. In up to half of young women the 
superior pituitary contour is convex, although the size of 
the pituitary rarely (0.5%) exceeds 9 mm (34, 35, 36, 37). 
The increase in height of the normal pituitary, generally 
observed in younger women, could be due to age-related 
changes of the hypothalamic–pituitary–gonadal axis (38, 
39). Lactotroph hyperplasia during pregnancy, thyrotroph 
hyperplasia due to severe primary hypothyroidism or 
pituitary hyperplasia due to hypersecretion of releasing 
hormones (corticotropin-releasing hormone and growth 
hormone-releasing hormone) should also be ruled out 
when such diffuse pituitary abnormalities are revealed on 
MRI (Fig. 4) (40, 41, 42, 43). Recent reports suggest that a 
lack of sex hormone feedback might induce development 
of pituitary hyperplasia in Klinefelter syndrome (44).
Technical artifacts
A number of artifacts may complicate the correct 
interpretation of sellar and parasellar MRI (30). They can 
easily mimic intrasellar lesions, in particular pituitary 
microadenomas. Partial volume artifacts occur when a 
3 mm thick cut includes parts of different anatomical 
structures, such as anterior pituitary gland and 
sphenoid sinus anteriorly, dorsum sellae posteriorly, or 
intracavernous internal carotid arteries laterally. In such 
cases the average intensity of the different components 
of the cut section calculated by the computer can 
simulate an intrasellar tumor. Partial volume effects can 
be eliminated by coupling orthogonal projections or by 
using 1 mm thick cuts. Magnetic susceptibility artifacts 
are responsible for geometrical distortion and localized 
signal intensity changes at the interface between 
anatomical structures with different signal intensities, 
predominantly in the case of a curved interface. Magnetic 
susceptibility artifacts are often present at the level of the 
sellar floor and are more pronounced on 3.0 T MRI, but 
these can be accounted for with technical adjustments. 
Chemical shift artifacts and ghosting are related to the 
high signal of fat. They can compromise the visualization 
Figure 2
Enlarged pituitary content of multiple origins in a female with intracranial hypotension after failed lumbar puncture. sagittal (a) 
and coronal (B) t1-weighted, coronal t1-weighted contrast-enhanced (c) and coronal t2-weighted (D) images reveal a large 
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of the storage of vasopressin in the posterior lobe on 
axial T1-weighted sections when the dorsum sellae is 
fatty, particularly on 3.0 T MRI. Fat saturation techniques 
can be useful in such cases. A prominent posterior lobe 
and its fossula hypophyseos sometimes can be mistaken 
for a posteriorly located pituitary adenoma on coronal 
T2-weighted images (Fig.  5). The topography of the 
posterior lobe itself, which is beyond the midline in 
about half of cases, is readily visualized on non-enhanced 
axial T1-weighted images. Flux artifacts arise mainly due 
to pulsating internal carotid arteries and cerebrospinal 
fluid. They are more severe on 3.0 T MRI and can blur or 
pollute the pituitary fossa or the subarachnoid spaces. All 
of these artifacts should be considered when clarifying 
the nature of incidental lesions in order to avoid possible 
mistakes in diagnosis.
Figure 4
Primary hypothyroidism in a 9-year-old girl. Regular 
enlargement of a homogeneous pituitary gland on sagittal (a) 
and coronal (B) t1-weighted images (upward convexity of the 
pituitary is shown with arrow).
Figure 3
Vascular anomalies narrowing the sellar content. ‘Kissing’ 
internal carotid arteries (arrows) on coronal t1-weighted 
image (a). trigeminal artery piercing the dorsum sella on 
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Determining the nature of pituitary 
incidentalomas
Pituitary adenomas and Rathke’s Cleft cysts (RCCs) are 
the most common entities in patients with pituitary 
incidentalomas and account for up to 90% of all lesions 
(6, 27, 28, 45). Other etiologies are less frequent – other 
tumors, mostly craniopharyngiomas in 4.2–5.6% and 
cystic malformations in 2.9–5.2% (46, 47, 48). It should 
be noted that these figures come generally from surgical 
series since definitive diagnosis is only possible after 
histopathological examination. The proportions of the 
two most common entities – pituitary adenomas and 
RCCs – also depend on the localization of the lesions. In 
cases of suprasellar lesions adenomas predominate, while 
RCCs are more common among intrasellar lesions.
The majority of incidental pituitary adenomas are 
small clinically non-functioning tumors. Secreting 
adenomas usually present with clinical symptoms of 
hypersecretion that facilitate their diagnosis, although 
subtle hormonal changes may not be clinically evident. 
In a recent study, 77% of incidentally discovered 
pituitary adenomas were found to be non-functioning, 
18% were prolactinomas and 3% were growth hormone 
secreting; the prevalences of different secretion patterns 
may be biased by the study population and the reason 
for pituitary imaging (28). Many large series of pituitary 
incidentalomas exclude hyperfunctioning adenomas 
and the overall prevalence of different secretory types 
is, therefore, not well established. Moreover, some 
patients with hypersecreting pituitary tumors discovered 
incidentally have clinical manifestations that were 
unrecognized at the initial examination (25). Such 
incidentally found functioning adenomas are usually 
prolactinomas. Unsuspected acromegaly can be revealed 
in some cases of pituitary incidentalomas (28, 49). 
Subclinical Cushing’s disease occurred in about 4% 
of histologically confirmed incidentaloma cases. 
Systematic screening for hypercortisolism and silent 
adrenocorticotropic hormone (ACTH)-secreting tumors 
should be considered at the time of identification of a 
pituitary incidentaloma (50).
Distinguishing pituitary adenomas from other non-
adenomatous lesions may be quite challenging. However, 
there are some radiological characteristics that may 
provide clues to the diagnosis.
Solid lesions
The differential diagnosis of a solid mass in the sellar 
regions should start with a pituitary adenoma. There may 
be areas of necrosis and hemorrhage with different signals 
on T1-weighted and T2-weighted sequences (51). In cases 
of cavernous sinus invasion, the internal carotid artery is 
usually unaffected (51). Intrasellar microadenomas (<10 
mm) have some specific characteristics: lateralization 
inside the adenohypophysis, possible deformation 
of the sellar diaphragm and displacement of the 
pituitary stalk. Classically, microprolactinomas appear 
hypointense on T1-weighted images and hyperintense on 
T2-weighted sequences (Fig. 6), while many GH-secreting 
microadenomas can be isointense or hypointense on 
T2-weighted sequences (46). The enhancement after 
contrast injection is often minimal. About 5–10% of 
microadenomas are discovered exclusively on post-
contrast images (30, 51, 52). Dynamic imaging with 
contrast is not always useful and may cause false-positive 
results. In 50% of normal glands, the posterior pituitary is 
off the midline (JF Bonneville, Personal Communication). 
If only the early phase of dynamic imaging is considered 
(when only the posterior pituitary but not the 
adenohypophysis is enhanced), this can falsely mimic a 
pituitary adenoma (Fig. 7).
Figure 6
Microprolactinoma. the adenoma (arrows) is t1-hypointense 
(a) and t2-hyperintense (B) on coronal images.
Figure 5
Posterior lobe mimicking a pituitary lesion on coronal 
t2-weighted image (arrow) (a). Deep fossula hypophyseos  
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Meningiomas are the second most common solid 
tumors in the pituitary region. They arise from the 
arachnoid cells of the dura and can often mimic the clinical 
picture of non-functioning pituitary adenomas with 
headache, visual disturbances and hypopituitarism (53). 
Their imaging characteristics, however, often can them to 
be distinguished from other sellar lesions (54). They usually 
do not enlarge the size of the sella and normal pituitary 
tissue can be visualized under the tumor. Meningiomas 
are isointense in T1-weighted images and hyperintense in 
T2-weighted images and tumor enhancement is intense 
and homogeneous with a linear thickening of the dura 
called the ‘dural tail’ (Fig.  8) (47). The internal carotid 
artery is often compressed when the meningioma invades 
the cavernous sinus (55). Substantial narrowing of the 
carotid lumen resulting in cerebrovascular insufficiency 
is, however, a rare event (56).
Tumors arising from the neurohypophysis like 
pituicytoma and granular cell tumors must also be 
considered when assessing intrasellar masses (48, 53). 
These lesions are usually isointense compared with 
gray matter in T1 and sometimes displace the normal 
adenohypohysis anteriorly. Although originating from 
the posterior lobe or the infundibulum, these tumors 
rarely cause diabetes insipidus. Taking into account 
that about 5–10% of germ cell tumors are found both in 
the suprasellar and pineal regions, the finding of such 
bifocal lesions can aid in the differential diagnosis. The 
suprasellar region is sometimes the origin of malignant 
primary brain tumors like gliomas originating from 
the optic tract/hypothalamus (46, 48, 57) Primary CNS 
lymphomas have also been described in the parasellar 
region (58). Malignant tumors, however, seldom remain 
silent for long and usually present with compression 
symptoms, hypopituitarism and diabetes insipidus. Their 
detection as an incidental finding would be extremely 
fortuitous. Some solid malignant tumors, especially breast 
and lung carcinomas, have been reported to metastasize 
rarely to the pituitary region. Metastasis usually affects 
the posterior lobe and presents with diabetes insipidus. 
In patients with a known primary tumor, likely 
metastatic lesions are not considered incidental findings. 
However, while searching for brain dissemination of a 
primary cancer, other non-metastatic pituitary lesions 
are more likely to be detected. Such cases can present 
serious clinical difficulties because metastatic lesions 
are similar to pituitary adenomas in appearance. Some 
distinguishing features of metastasis, albeit non-specific, 
include loss of posterior lobe bright spot and thickening 
of the pituitary stalk, bone erosions, and invasion of the 
sellar diaphragm (46, 48). PET has also been suggested 
Figure 7
normal dynamic imaging (a, B and c). Panel (c) shows 
magnification of normal delayed enhancement of the anterior 
pituitary simulating a pituitary adenoma (arrow). Panel (D) 
shows normal off-midline location of the posterior lobe 
(arrow) on an axial t1-weighted image.
Figure 8
Presellar meningioma. sagittal t1-weighted (a) and 
t2-weighted (B) sequences and contrast-enhanced 
t1-weighted sagittal (c) and coronal (D) images demonstrate 
a meningioma inserted on the planum sphenoidale (arrow). It 
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as being useful to differentiate malignant from benign 
lesions. Positive PET findings can be consistent with 
malignant lesions rather than benign ones (59). There is 
a significant overlap, however, between the appearances 
of metastatic lesions, meningiomas and adenomas 
on PET images, hence caution should be used in their 
interpretation (13, 14, 60).
Chordomas and chondromas are rare bone-
destroying tumors that arise from the primary notochord 
and cartilaginous remnants respectively (48). They 
can mimic invasive macroadenomas with inferior 
expansion (51). Occasionally the normal pituitary 
tissue can be distinguished above the tumor, which 
can help in its differentiation from invasive pituitary 
adenomas (61). Lymphocytic hypophysitis is another 
entity to be considered in the differential diagnosis of 
symmetric homogeneous enlargement of the pituitary. 
This autoimmune disorder usually affects women in 
the peripartum period and is characterized by frequent 
suprasellar extension, thickening of the stalk and 
intensive contrast accumulation (Fig. 9) (62, 63). Again, 
most of these conditions are associated with clinical 
symptomatology and would be exceptional findings if 
discovered fortuitously.
Cystic lesions
Incidentally found cystic lesions in the sellar and 
parasellar region need to be distinguished from a 
necrotic pituitary adenoma and non-pituitary entities 
such as RCCs, dermoid and epidermoid cysts, and cystic 
craniopharyngiomas. Necrotic macroadenomas usually 
lead to sellar enlargement and the walls of the tumor 
show distinct contrast uptake (51). A fluid level may be 
present in some cases.
RCCs are malformations that originate from the 
remnant of the squamous epithelium of Rathke’s pouch and 
consist of a single layer of cuboidal or columnar epithelial 
cells filled with cystic components (64, 65). RCCs occur 
mostly in adults and usually are small and asymptomatic 
and as such they are the most common cystic pituitary 
incidentaloma and can be found in up to 22% at autopsy 
(46). Most of these lesions are intrasellar, but they can 
also lie on the sellar diaphragm, as ‘an egg in an egg cup’ 
(Fig.  10). They can expand above the sellar region and 
may become symptomatic causing compression of the 
optic tract or pituitary dysfunction. The basal MRI signal 
of RCC is highly variable and depends on the content of 
the cyst, which can be serous or mucinous (66). They are 
more frequently hyperintense on T1-weighted images. 
Characteristic of RCC are T2-hypointense intracystic 
nodules formed by cholesterol and are observed in 70% 
of T1-hyperintense RCC. Usually the cyst wall does not 
enhance after contrast administration, except in cases of 
complications such as infection, hemorrhage or rupture 
(Fig. 11) (64). Intrasellar RCCs cause no or limited mass 
effects, whereas pituitary adenomas may imprint the 
bony contours of the sella, compress the posterior lobe 
and displace the pituitary stalk.
Figure 10
Mucoid t1-hyperintense Rcc on axial t1-weighted image (a), 
located in the midline between the anterior and posterior 
lobes. a coronal t1-weighted image (B) shows an Rcc on the 
upper surface of the pituitary, as an ‘egg in an egg cup’.
Figure 9
Lymphocytic hypophysitis. coronal t1-weighted (a) and 
t2-weighted (B) sequences and contrast-enhanced 
t1-weighted coronal (c) and sagittal (D) images show 
enlarged sellar content abutting the optic chiasm (curved 
arrow). the lesion is t1-isointense, t2-hyperintense, and 
becomes markedly enhanced after gadolinium injection. the 
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About 50% of craniopharyngiomas occur in children 
and adolescents, but there is also another peak of 
occurrence in the elderly (67). They arise from squamous 
cells of the remnants of Rathke’s pouch and can be 
predominantly cystic, predominantly solid or mixed 
in nature. Calcifications are present in two-thirds of all 
cases and in almost all cases in children (68). Although 
craniopharyngiomas are benign tumors, they usually 
have an aggressive behavior and a tendency to infiltrate 
(69). Hence, they rarely remain asymptomatic and most 
commonly present with headache, visual disorders, 
hypopituitarism and diabetes insipidus. In children, 
however, these symptoms may not be recognized initially 
and diagnosis can be delayed (67). The appearance 
on MRI varies depending on the proportion of solid 
and cystic components, the presence or absence of 
calcification, and the contents of the cyst (70). The solid 
portion of craniopharyngiomas usually appears isointense 
or hypointense on T1-weighted and hyperintense on 
T2-weighted sequences. The cystic part is hyperintense on 
T1-weighted sequences with a thin contrast-enhancing 
rim (71). Although calcifications are not specific, they are 
very characteristic of a craniopharyngioma (46, 72, 73, 
74, 75). In all patients with an incidentally discovered 
pituitary lesion and a suspicion of a craniopharyngioma, 
both MRI and CT should be performed to establish a 
definitive diagnosis.
Dermoid and epidermoid cysts are other lesions that 
often arise in the midline in the sellar and parasellar 
region. They include epithelial elements resulting from 
incomplete separation of the neuroectoderm from the 
cutaneous ectoderm (48). Their imaging characteristics 
are non-specific and their differentiation from other cystic 
lesions may be difficult. Dermoid cysts usually contain fat 
components and are heterogeneous on T1 images and 
hyperintense on T2 images (46, 65, 76). Epidermoid cysts 
contain keratin and are almost identical in appearance to 
cerebrospinal fluid with no contrast enhancement (65). 
Arachnoid cysts are rare herniations of the arachnoid 
diverticulum through the sellar diaphragm and can be 
intrasellar or suprasellar (76). On MRI they appear as well-
defined lesions that are isointense to cerebrospinal fluid 
on T1-weighted and T2-weighted sequences and are not 
enhanced by gadolinium (74).
To treat or not to treat?
Once a pituitary incidentaloma has been discovered 
and a differential diagnosis made, the clinician is faced 
with a decision about what to do. The management 
of incidentally found sellar lesions depends on the 
suspected nature of the tumor (pituitary adenoma, 
RCC, craniopharyngioma, etc.), its size and clinical 
symptomatology (visual and neurological disorders), and 
hormonal status (hyposecretion/hypersecretion/normal 
secretion). Thorough clinical examination should be 
performed for signs and symptoms of hypersecretion or 
hyposecretion that may have been overlooked, followed 
by hormonal evaluation. Close attention to normal 
and physiological variations and technical artifacts 
can help to avoid unnecessary surgical interventions. 
Neurosurgery remains the treatment of choice for many 
secreting and non-secreting pituitary lesions causing 
visual abnormalities due to compression of optic chiasm 
and signs of tumor mass effect. Diabetes insipidus 
occurs infrequently in pituitary adenomas, whereas it is 
a common clinical manifestation associated with other 
pituitary lesions, particularly pituitary metastases (77). 
The age of the patients and their general health status 
are important issues that need to be considered when 
deciding the treatment strategy.
Medical therapy with dopamine agonists and 
somatostatin analogs can produce tumor shrinkage in 
the case of prolactinomas and acromegaly respectively, 
which may provide important clinical improvements. 
Usually surgical referral is also indicated in many of 
other lesions in the sellar and parasellar regions like 
meningiomas, craniopharyngiomas and other less 
frequent tumors as well as large cysts when these cause 
compression symptoms. Infiltrative lesions, however, 
like lymphocytic and granulomatous hypophysitis are 
largely managed conservatively, except when symptoms 
are severe or progressive – in such cases surgery may 
Figure 11
Rcc on coronal t1-weighted image after gadolinium injection. 
Panel (a) shows the usual pattern: the cyst wall is not 
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be performed or corticosteroids may be used. (63, 78, 
79, 80) Primary lymphomas in the region are managed 
with chemotherapy and radiotherapy and rarely surgically, 
although stereotactic biopsy may be needed for accurate 
diagnosis (61).
As the vast majority of pituitary incidentalomas are 
non-functioning pituitary adenomas and most of these 
are microadenomas, the decision about their management 
is determined by their growth potential. The behavior of 
incidentally found pituitary adenomas has been studied 
by a number of separate groups worldwide (25, 49, 81, 
82, 83, 84). Based on the current data regarding the 
natural history of small incidentally discovered non-
functioning adenomas, watchful waiting is considered 
the most appropriate strategy (1). The growth potential 
of non-functioning pituitary adenomas is heavily 
dependent on their size at diagnosis, with larger tumors 
having greater growth potential. In a systematic review 
and meta-analysis, Fernandez-Balsells and coworkers. 
reviewed the natural history of incidentalomas and 
non-functioning pituitary adenomas (85). In a group 
of 11 studies (patient number ranged from 50 to 289 
per study), the authors reported a higher incidence of 
tumor growth in macroadenomas and solid lesions as 
compared with microadenomas and cystic lesions (85). 
Macroadenomas and microadenomas had incidences of 
tumor growth of 12.53 and 3.32 per 100 patient-years 
respectively. Although data quality was poor (due to 
small numbers of studies with heterogeneous designs), 
macroadenomas had a significantly higher incidence 
of new endocrine dysfunction (11.9 per 100  patient-
years) and visual field worsening (0.5 per 100  patient-
years), as compared with microadenomas (85). In other 
detailed reviews, tumor enlargement occurred in 10% 
Figure 12
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of microadenomas, with tumor reduction seen in 6% 
during 2.5–8 years of observation (2). In contrast, tumor 
growth in macroadenomas can occur in up to 24% of 
cases (2, 73).
The development and worsening of clinical 
symptoms  such as visual disturbances and the 
occurrence of apoplexy directly depend on tumor 
size and most frequently occur in growing tumors (2, 
10, 85, 86, 87), although visual loss may be reversible 
in most cases (83, 88, 89). Macroadenomas are also 
the usual cause of hypopituitarism in patients with 
pituitary incidentalomas (28). The presence of partial 
or panhypopituitarism varies greatly in published series 
(0–41% of macroadenomas) (1, 2). In cases of significant 
growth of pituitary adenomas during follow-up or the 
development of compression symptoms such as visual 
field defects and vision abnormalities, surgical treatment 
must be strongly considered (1). Although surgery 
can improve hypopituitarism, further worsening of 
hypopituitarism due to surgery itself may occur.
Cystic lesions increase in size less frequently than 
solid tumors (85). During follow-up, 20% of 115 non-
functioning adenomas enlarged over the course of 10–173 
months, while only 5.3% of 94 probable RCCs increased 
in size. Furthermore, more than 50% of tumors that 
decrease in size are cystic (25). Thus, many RCCs and 
other cystic lesions may stay stable without growth and 
might be safely followed up with careful laboratory 
and radiological evaluation (1, 90).
The duration and periodicity of radiological 
follow-up also depends on tumor nature and size. Current 
consensus guidelines recommend performing a follow-up 
MRI 6 months after the initial incidental discovery 
for macroadenomas and after 1 year the discovery for 
microadenomas. When no tumor growth is observed, MRI 
should be repeated annually for macroadenomas and every 
1–2 years for microadenomas for the next 3 years and less 
frequently afterward, if no growth occurs. Others have even 
suggested that no surveillance needs to be implemented 
for non-functioning microadenomas <5 mm in size, 
although this approach could miss the rare lesions that 
expand aggressively (51). Baseline hormonal evaluation is 
warranted, both to establish whether any clinically relevant 
endocrine change is present at diagnosis, and to provide a 
yardstick to assess any change overtime. In asymptomatic 
patients with incidentally found microadenomas, the 
costs of evaluation can be significant. While data are not 
widely available for different countries, the US experience 
suggests the initial evaluation costs >6000 US dollars 
per patient (not including follow-up assessments) (91). 
Cost containment will require improved understanding 
of the growth potential of pituitary incidentalomas and 
adherence to existing guidelines/recommendations to 
avoid unnecessary expenses in long-term follow-up, 
particularly of chronically stable small lesions (1).
For accurate follow-up evaluation of pituitary 
incidentalomas, particularly non-functioning adenomas, 
the question of MRI reproducibility is significant. Ideally, 
the follow-up analysis should be performed at the same 
clinical center, using the same imaging protocols for more 
precise and easier comparison with previous images.
Conclusions
Increased availability of high-quality neuroimaging 
techniques has led to a rise in the detection of incidental 
pituitary lesions, and their evaluation is becoming more 
common in everyday endocrine practice. In the case 
of a fortuitously discovered sellar or parasellar lesion, 
the initial workup should be focused on distinguishing 
pathological conditions from normal or physiological 
variants. A suggested diagnostic pathway is outlined in 
Fig.  12. Since imaging characteristics provide valuable 
clues for the differential diagnosis, close collaboration 
among specialists in radiology, endocrinology and 
neurosurgery is required. The majority of incidentally 
found pituitary lesions turn out to be non-functioning 
pituitary adenomas or RCCs and current data suggest 
that they can be managed conservatively in most cases 
by periodical MRI monitoring allied with simple clinical 
surveillance. Large or growing lesions, or pituitary 
lesions associated with hormonal or local symptoms, 
require active and regular follow-up by multidisciplinary 
treatment teams.
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